# A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer

> **NCT07253142** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 120 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Small Cell Lung Cancer

## Interventions

- **DRUG:** HLX43 dose 1
- **DRUG:** HLX43 dose 2

## Key facts

- **NCT ID:** NCT07253142
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-14
- **Primary completion:** 2027-06-18
- **Final completion:** 2028-06-19
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07253142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07253142, "A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT07253142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*